


I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office, Technical Center 1600, Fax No. 1-703-872-9306 on

**PATENT**  
Attorney Docket No.: 15270J-004738US

March 17, 2005.

TOWNSEND and TOWNSEND and CREW LLP

By: 

**RECEIVED  
CENTRAL FAX CENTER**

MAR 17 2005

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

SCHENK, Dale B.

Application No.: 10/815,404

Filed: March 31, 2004

For: PREVENTION AND TREATMENT OF  
AMYLOIDOGENIC DISEASE

Examiner: Laurie Scheiner

Art Unit: 1648

**REVISED TERMINAL DISCLAIMER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

The undersigned is an authorized representative of Neuralab Limited (hereinafter "ASSIGNEE") and attorney of record in the above-identified patent application. ASSIGNEE is the assignee of total interest of:

1. Application No. 10/815,404 (the "APPLICATION")
2. Application No. 09/723,927 Issued as U.S. Patent No. 6,787,138 (the "PATENT")

SCHENK, Dale B.  
Application No.: 10/815,404  
Page 2

PATENT

ASSIGNEE is the exclusive owner of the APPLICATION and the PATENT.  
ASSIGNEE disclaims the terminal part of any patent granted on the APPLICATION which would extend beyond the last day of the full statutory term of the PATENT.

Further, ASSIGNEE agrees that any patent granted on the APPLICATION shall be enforceable only for and during the period that the legal title to the patent granted on the APPLICATION shall be the same as the legal title to the PATENT and agrees that this Terminal Disclaimer shall run with any patent granted on the APPLICATION and shall be binding on the grantee or its successors or assigns.

In making the above disclaimer, ASSIGNEE does not disclaim the terminal part of any patent granted on the APPLICATION that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the PATENT, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

This disclaimer is directed to patents issuing from the indicated APPLICATION only and is not intended to act as a disclaimer of any part of the statutory term of any patent issuing from a divisional or continuation application that claims priority to either the APPLICATION or to use the term of such a patent issuing from a divisional or continuation application in calculating the term of the present APPLICATION.

The assignment documents evidencing title referred to above have been reviewed by the undersigned, and it is certified that title is in the ASSIGNEE.